Rowatinex Oral Drops, Solution

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Anethol; Alpha pinene; Borneol; Fenchone; Camphene; Cineole; Beta pinene

Available from:

Rowa Pharmaceuticals Limited

INN (International Name):

Anethol; Alpha pinene; Borneol; Fenchone; Camphene; Cineole; Beta pinene

Dosage:

percent volume/volume

Pharmaceutical form:

Oral drops, solution

Prescription type:

Product not subject to medical prescription

Authorization status:

Not marketed

Authorization date:

1983-04-01

Patient Information leaflet

PACKAGE LEAFLET: INFORMATION FOR THE USER
ROWATINEX
®
ORAL DROPS, SOLUTION
Α-PINENE, Β-PINENE, CAMPHENE, BORNEOL, ANETHOL, FENCHONE, CINEOLE
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your doctor or pharmacist
has told you.
- Keep this leaflet. You may need to read it again.
- Ask your pharmacist if you need more information or advice.
- If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
- You must talk to a doctor if you do not feel better or if you feel
worse.
WHAT IS IN THIS LEAFLET:
1. What Rowatinex® is and what it is used for
2. What you need to know before you take Rowatinex®
3. How to take Rowatinex®
4. Possible side effects
5. How to store Rowatinex®
6. Contents of the pack and other information
1. WHAT ROWATINEX® IS AND WHAT IT IS USED FOR
Rowatinex® helps to dissolve/break down and remove (disintegrate and
eliminate) kidney
and urinary tract stones.
Rowatinex® relieves muscle spasm thus reducing the pain of renal and
urinary colic. It
increases blood flow and reduces inflammation, which could be
associated with the
presence of kidney stones.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ROWATINEX®
DO NOT TAKE ROWATINEX®:
-
if you are allergic to α-pinene, β-pinene, camphene, borneol,
anethol, fenchone, cineole
or any of the other ingredients of this medicine (listed in section
6).
WARNINGS AND PRECAUTIONS
TALK TO YOUR DOCTOR FIRST BEFORE YOU TAKE ROWATINEX®
DO NOT TAKE ROWATINEX FOR TREATMENT OF URINARY STONES
UNLESS YOUR DOCTOR HAS CONFIRMED A
DIAGNOSIS OF URINARY STONES ESPECIALLY IN THE CASE OF CHILDREN.
Talk to your doctor or pharmacist before taking Rowatinex® if you are
taking medicines to
thin your blood or medicines that are broken down by the liver.
OTHER MEDICINES AND ROWATINEX®
Tell your doctor or pharmacist if you are taking, have recent

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Rowatinex Oral Drops, Solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 100 g of oral drops solution contains:
-Pinene 24.8 g,
-Pinene 6.2 g, Camphene 15.0 g, Borneol 10.0 g, Anethol 4.0 g,
Fenchone 4.0 g, Cineole 3.0 g.
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Oral Drops, solution
Pale yellow to greenish yellow oral drops solution with a strong
aromatic odour.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
In the management of urolithiasis WHERE A DEFINITE DIAGNOSIS HAS BEEN
MADE BY A DOCTOR ESPECIALLY IN THE CASE OF
CHILDREN.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Method of Administration: Oral.
Adults: 3 to 5 oral drops 4 to 5 times daily before meals or in the
presence of colic 20 to 30 oral drops 4 to 5 times
daily.
_Paediatric Population_
Children aged 0 to 6 years: No data are available
Children aged 6 to 14 years: 1 to 2 oral drops twice daily before
meals.
Adolescents aged 14 to 18 years: 3 to 5 oral drops 4 to 5 times daily
before meals or in the presence of colic 20 to 30
oral drops 4 to 5 times daily.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance(s) or to any of the
excipients listed in section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_5_
_/_
_0_
_3_
_/_
_2_
_0_
_1_
_8_
_C_
_R_
_N_
_ _
_2_
_1_
_9_
_7_
_9_
_8_
_1_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
DEFINIT